Introducing Endora Health

Continuous Hormonal Fluency

April 2026: Seed Funding (Series A1)

Discover The System

1.2 Billion Women are Hormonally 'Blind'.

From Perimenopause to Longevity Management, women lack the data needed to manage Hormonal Volatility.

Current testing is episodic (blood draws) or invasive (microneedles).
Focus is on point-in-time clinical events (IVF), ignoring the 10-year longevity journey.
We've moved the lab to the cheek.

Antiquated Blood Draws

Scattered, noisy data points for continuous physiologic systems.

Continuous, Microneedle-Free Map.

We provide frictionless, continuous feedback for endocrine health. Zero needles. Zero hassle.

Form Factor: A 5mm buccal (cheek) mucoadhesive "sticker."
Mechanism: GFET sensor detects "free" hormones in saliva wicks.
UX: 48-hour wear. Seamless NFC syncing to the Endora App.

Invisible, Effortless UX

A non-invasive patch on the inner cheek. Invisible to the world.

The GFET Breakthrough.

Leveraging 2D material science (Graphene Electronic Multiplexed Sensors - GEMS) for picomolar ($10^{-12}$) sensitivity. We detect the hormones that microneedles miss.

GFET Sensitivity

A single layer of graphene acts as a super-conductive sensor surface.

Picomolar Accuracy

DNA 'Aptamers' capture hormones; Graphene detects the charge instantly.

The Endora Inflection Point.

LZH and Symex are using 2024 technology. We leverage 2026 breakthroughs.

1.

Regulatory Fast-Track

FDA Jan 2026 Guidance grants discretion to non-invasive trend sensors.

GTM in 9 months.

2.

Graphene Foundries

GFET production is commercial (Paragraf/Graphenea), CMOS-scale.

Sensor Unit Cost <$3.00.

3.

Longevity Model

FemTech has shifted from fertility to continuous lifespan management.

10-Year Customer Lifecycle.

Rigor: Stress-Tested Engineering.

The mouth is a complex environment. We have built the technical 'moat' to handle it.

✦ Nanoporous Membrane: Blocks mucins/bacteria (fouling barrier)

✦ Reference GFET: Subtracts pH and Ion noise in real-time

✦ Ratiometric: Normalizes against Creatinine to handle flow dilution

The Regulatory Bridge: Wellness-to-Clinical.

Revenue on Day 1. Diagnostic clearance on Day 500.

Step 1: Wellness

Months 1–12 (2026 Launch)

Cycle Mapping, Sleep, Stress Optimization

(FDA Jan 2026 Wellness)

Step 2: Clinical

Months 12–36+

HRT Titration, IVF Support, PCOS Diagnosis

(FDA De Novo / 510k)

From Clinical Niche to Longevity Ocean.

Our frictionless UX unlocks the largest customer base in FemTech: Perimenopause and Longevity.

Business Model

Hardware + App Subscription: $39/mo

TAM

$1.2T

Global Women's Health
+ Longevity Markets

The Opportunity

A Defensible Technical Moat.

We win on Friction and Frequency. LZH cannot compete on the consumer experience.

Feature	Endora Health	Competitors (LZH/Symex)	Eli Health	Surrogates (Oura)
Invasive?	Zero	Minimal (Microneedle)	Zero	Zero
Frequency	Continuous (48hr Wear)	Continuous	Snapshot (One-off)	Inferred (Surrogate)
Sensitivity	$10^{-12}$ (Picomolar)	$10^{-9}$ (Nanomolar)	Picomolar	N/A
Manufacturing	High (CMOS Fab)	Low (Mechanical)	Moderate	High
Primary Play	Consumer Longevity (Wellness)	Clinical IVF (510k)	Snapshot Monitoring	Surrogate Wellness

Seed Round: The Endocrine Map.

The race for continuous hormone monitoring has begun. Endora has the technology and regulatory moat to win.

Ask: $6.5M

Reach 10,000 Users and Complete Parity Study.

[M1-M3] Foundry Agreement (Graphenea / Paragraf)
[M4-M6] Prototype Validation vs Lab Blood Lab (N=100)
[M9] Endora Alpha Launch (10,000 Power Users)

Contact Us to Join